drugset / Trial / NCT05095207
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Timeline
- Start
- 2021-09-20
- Primary completion
- 2027-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 50 mg | Oral |
| Subject | Abemaciclib | Small molecule | 100 mg | Oral |
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |